Antitumor enhancement of celecoxib, a selective Cyclooxygenase-2 inhibitor, in a Lewis lung carcinoma expressing Cyclooxygenase-2.

J Exp Clin Cancer Res · 2008 · PMC2621123 · PMID 19000324

Europe PMC DOI

hedged sentence

0.0675

closest p · 1.4× alpha

0.0675

boldest claim

The sentences

only marginally significantp = 0.0675so close (0.05 < p ≤ 0.1)

The mean metastatic area was the smallest in mice treated with irradiation and 75 mg/kg celecoxib daily (group 6); however, the difference was only marginally significant (p = 0.0675).

also in 5,072 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.